Methsuximide
(Synonyms: 甲琥胺,(±)-Mesuximide,PM 396) 目录号 : GC17442
An anticonvulsant
Cas No.:77-41-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Methsuximide (or methsuximide, methosuximide, Celontin) is a succinimide anticonvulsant medication that is pharmacologically converted to its active metabolite N-desmethylmethosuximide, a channel blocker that targets low threshold calcium currents.
Methsuximide effectively suppressed the initial clonic seizures induced by Metrazol in rats and mice. Methsuximide was capable of protecting mice from tonic extensor seizures to supramaximal electroshock [2]. In children with intractable epilepsies, administration of MSM greatly reduced the seizure frequency with no serious or irreversible adverse effects [3].
Methsuximide can function as a substrate of cytochrome P450 (CYP) isoform 2C19 which in turn, inhibits CYP2C19-mediated metabolism of biguanides [4]. Cytochrome P450 2C19 (abbreviated CYP2C19) is an enzyme involved in the metabolism of xenobiotics. Polymorphism of CYP2C19is has been associated with variable ability to metabolize mephenytoin [5].
References:
[1] Nicholls, P. J., and Orton, T.C. The physiological disposition of 14C-methsuximide in the rat. Br.J.Pharmacol. 45(1), 48-59 (1972).
[2] Chen G, Weston J K, Bratton A C. Anticonvulsant activity and toxicity of phensuximide, methsuximide and ethosuximide[J]. Epilepsia, 1963, 4(1‐4): 66-76.
[3] Sigler M, Strassburg H M, Boenigk H E. Effective and safe but forgotten: methsuximide in intractable epilepsies in childhood[J]. Seizure, 2001, 10(2): 120-124.
[4] Wright J D, Helsby N A, Ward S A. The role of S‐mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides[J]. British journal of clinical pharmacology, 1995, 39(4): 441-444.
[5] Guengerich F P. Human cytochrome P450 enzymes[M]//Cytochrome P450. Springer US, 1995: 473-535.
| Cas No. | 77-41-8 | SDF | |
| 别名 | 甲琥胺,(±)-Mesuximide,PM 396 | ||
| 化学名 | 1,3-dimethyl-3-phenyl-2,5-pyrrolidinedione | ||
| Canonical SMILES | CN(C(CC1(C)C2=CC=CC=C2)=O)C1=O | ||
| 分子式 | C12H13NO2 | 分子量 | 203.2 |
| 溶解度 | ≥ 8.35mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.9213 mL | 24.6063 mL | 49.2126 mL |
| 5 mM | 0.9843 mL | 4.9213 mL | 9.8425 mL |
| 10 mM | 0.4921 mL | 2.4606 mL | 4.9213 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet